• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    NexGel Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits

    5/20/24 6:15:32 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care
    Get the next $NXGL alert in real time by email
    false 0001468929 0001468929 2024-05-15 2024-05-15 0001468929 NXGL:CommonStockParValue0.001Member 2024-05-15 2024-05-15 0001468929 NXGL:WarrantsToPurchaseCommonStockMember 2024-05-15 2024-05-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): May 15, 2024

     

    NEXGEL, INC.
    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41173   26-4042544

    (State or other jurisdiction

    of incorporation)

      (Commission
    File Number)
     

    (IRS Employer

    Identification No.)

     

    2150 Cabot Boulevard West, Suite B

    Langhorne, Pennsylvania

      19067
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (215) 702-8550

     

    (Former name or former address, if changed since last report)

    Not Applicable

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001   NXGL   The Nasdaq Capital Market LLC
    Warrants to Purchase Common Stock   NXGLW   The Nasdaq Capital Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     
     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On May 15, 2024 (the “Closing Date”), NexGel, Inc., a Delaware corporation (the “Company”), entered into and closed a transaction related to an Asset Purchase Agreement dated May 15, 2024 (the “Purchase Agreement”) with Semmens Online Pty Ltd as Trustee for Semmens Business Trust, an Australian proprietary limited (the “Seller”), whereby the Company purchased all assets related to the Seller’s eyeliner, fake eyelashes, lash growth serum and mascara business operating under the tradename “Silly George” (collectively, the “Business”).

     

    Under the terms of the Purchase Agreement and on the Closing Date, the Company paid the Seller a cash payment of $400,000 (the “Initial Cash Payment”) and will issue within 5 trading days of the Closing Date $200,000 in shares of the Company’s common stock based on the 10-Day VWAP (as defined in the Purchase Agreement), or 89,892 of shares of the Company’s common Stock (the “Stock Payment”). The Initial Cash Payment is not subject to any escrow conditions. Additionally, the Company shall pay the Seller a cash earn-out based on 20% of the Net Profit (as defined in the Purchase Agreement) related to the Business for the fiscal quarterly period beginning June 30, 2024 and ending on June 30, 2028 2024 (the “Earn-Out Payments”). The Initial Cash Payment, the Stock Payment and Earn-Out Payments are collectively referred to herein as the Purchase Price.

     

    The Purchase Agreement and the transaction contemplated thereby are not subject to approval by the shareholders of the Company. The Purchase Agreement contains standard representations and warranties regarding the Seller and the Business and certain limited representations and warranties regarding the Company. The Purchase Agreement also contains indemnification provisions for the benefit of the Company and the Seller. Neither the Company nor the Seller shall be liable for more than 60% of the Purchase Price under the indemnification provisions except in the case of fraud or willful misconduct. The Seller and the Seller’s director and owner agreed to 5-year non-compete provisions as part of the Purchase Agreement.

     

    This summary of certain terms of the Purchase Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Purchase Agreement, a copy of which is attached hereto as Exhibit 10.1 and is hereby incorporated into this Current Report on Form 8-K (this “Form 8-K”) by reference.

     

    The Purchase Agreement has been included solely to provide investors and security holders with information regarding its terms. It is not intended to be a source of financial, business or operational information, or to provide any other factual information, about the Company, the Seller or their respective subsidiaries or affiliates. The representations, warranties and covenants contained in the Purchase Agreement are made only for purposes of the Purchase Agreement and are made as of specific dates; are solely for the benefit of the parties (except as specifically set forth therein); may be subject to qualifications and limitations agreed upon by the parties in connection with negotiating the terms of the Purchase Agreement; and may be subject to standards of materiality and knowledge applicable to the contracting parties that differ from those applicable to investors or security holders. Investors and security holders should not rely on the representations, warranties and covenants or any description thereof as characterizations of the actual state of facts or condition of the Company, the Seller or any of their respective subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations, warranties and covenants may change after the date of the Purchase Agreement, as applicable, which subsequent information may or may not be fully reflected in public disclosures.

     

    Item 2.01. Completion of Acquisition or Disposition of Assets.

     

    The information set forth in Item 1.01 of this Form 8-K is incorporated herein by reference in its entirety.

     

     
     

     

    Item 3.02. Unregistered Sales of Equity Securities.

     

    The information set forth in Item 1.01 of this Form 8-K is incorporated herein by reference in its entirety.

     

    The Stock Payment is being issued in a private placement transaction that will rely upon an exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The shares of the Company’s common stock issued in connection with the Stock Payment will be “restricted securities” as such term is defined by the Securities Act.

     

    Item 8.01. Other Events.

     

    On May 16, 2024, the Company issued a press release announcing the acquisition of the Business. A copy of the press release is filed as Exhibit 99.1 hereto and incorporated herein by reference in its entirety.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (a) Financial statements of business acquired.

     

    (b) Pro forma financial information.

     

    No financial statements and/or pro forma financial information will be required to be filed with the Securities and Exchange Commission relating to the acquisition of the Business.

     

    (d) Exhibits

     

    10.1 Asset Purchase Agreement dated May 15, 2024 between NexGel, Inc. and Semmens Online Pty Ltd as Trustee for Semmens Business Trust (schedules and exhibits identified in the Purchase Agreement have been omitted pursuant to Item 601b.2 of Regulation S-K).
    99.1 Press release issued by NexGel, Inc. on May 16, 2024.
    104 Cover Page Interactive Data File (formatted as Inline XBRL)

     

     
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: May 20, 2024    
         
      NEXGEL, INC.
         
      By: /s/ Adam Levy
       

    Adam Levy

    Chief Executive Officer

     

     

    Get the next $NXGL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXGL

    DatePrice TargetRatingAnalyst
    2/25/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $NXGL
    SEC Filings

    View All

    NexGel Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - NEXGEL, INC. (0001468929) (Filer)

    3/10/26 9:17:26 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NexGel Inc filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - NEXGEL, INC. (0001468929) (Filer)

    2/11/26 8:33:07 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    SEC Form 424B5 filed by NexGel Inc

    424B5 - NEXGEL, INC. (0001468929) (Filer)

    2/10/26 4:13:16 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio  Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing LANGHORNE, Pa., March 12, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the consideration terms of its

    3/12/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    Celularity Reiterates Strategic Commercialization Partnership with NEXGEL Focused on Building Biomaterials Franchise with Established Commercial Products and New 510(k) Pathway Product Opportunities

    Biovance, Biovance 3L, Natalin, Acelagraft, Interfyl and Centaflex licensed to NEXGEL are established commercial products widely used today in wound care, orthopedics and other indications.Three pipeline 510(k) medical device pathway programs SPARK, FUSE, and ORCHID licensed to NEXGEL are potential market disruptors.Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility in Florham Park, New Jersey, where its vertically integrated manufacturing infrastructure is designed to support scalable, quality-driven production for both commercial-stage products and next-generation placental-derived cellular therapeutics. FLORHAM PARK, N.J., March 12, 2026

    3/12/26 8:30:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    $NXGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Levy Adam R. bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 1% to 333,196 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:14 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Zeldis Jerome B bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 4% to 106,664 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:12 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Stein John Nachum gifted 4,000 shares and bought $9,999 worth of shares (3,636 units at $2.75), decreasing direct ownership by 0.08% to 471,456 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:08 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Levy Adam R. sold $15,947 worth of shares (10,000 units at $1.59), decreasing direct ownership by 3% to 357,692 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    12/29/25 8:47:06 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Levy Adam R. sold $10,084 worth of shares (4,000 units at $2.52), decreasing direct ownership by 1% to 367,692 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/7/25 8:00:07 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Henry Scott Robert sold $20,360 worth of shares (8,000 units at $2.55), decreasing direct ownership by 7% to 113,356 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    10/6/25 8:00:05 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on NexGel with a new price target

    Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00

    2/25/22 9:17:01 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products

    Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr

    3/10/26 8:45:00 AM ET
    $CELU
    $NXGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments

    NexGelRx Receives Additional Investment from Eric Gruntfest of Diesis Holdings, LLC and Appoints Him as Board Observer and Strategic Advisor

    LANGHORNE, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced that NexGelRx, the Company's previously announced spin-off of select drug delivery application assets, has received strategic investments from Eric Gruntfest and Ariel Imas of Diesis Holdings, LLC. In connection with the investment, NexGelRx has appointed Mr. Gruntfest to serve as a board observer and advisor, bringing deep experience in reimbursement strategy, patient access, and healthca

    12/16/25 8:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors

    LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:SSTK), Mr. Ciardiello has a proven track record of financial leadership, strategic execution, and corporate governance in high-growth, publicly traded companies. "Steve's extensive experience, financial leader

    8/5/25 8:00:00 AM ET
    $NXGL
    $SSTK
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    $NXGL
    Financials

    Live finance-specific insights

    View All

    NEXGEL Reports Third Quarter 2025 Financial Results

    LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its third quarter 2025 financial results for the period ending September 30, 2025. Third Quarter 2025 Financial Highlights: Net Revenue was $2.93 million, compared to $2.94 million in Q3 2024 and $2.88 million in Q2 2025.Gross Profit was $1.24 million, compared to $1.16 million in Q3 2024 and $1.26 million in Q2 2025.Gross Profit Margin was 42.4%, compared to 39.3% in Q3 2024 and 43.6% i

    11/11/25 4:10:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL to Report Third Quarter 2025 Financial Results on November 11th

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the third quarter 2025, after the market close on November 11, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Third Quarter 2025 Financial Results Conference CallDate: November 11, 2025Time: 4:3

    11/3/25 8:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Reports Second Quarter 2025 Financial Results

    Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the perio

    8/12/25 4:05:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care